AC Immune Posts 13-Cent Quarterly Loss, Cash Runs Into 2028
ACIU is trading near its 52-week low of $2.015 (7.2% above the low).
Summary
AC Immune reported a third-quarter loss of 13 cents per share on revenue of $3.24 million. The company ended the quarter with CHF 73.9 million in cash, which management says funds operations into the first quarter of 2028. For a clinical-stage biotech with a roughly $213 million market cap, that runway statement is the number that matters — it removes near-term financing risk while the pipeline reads out. The loss itself is routine for a company with no product revenue. The setup follows a strong stretch of data: FDA Fast Track and IND clearance for the Parkinson's immunotherapy ACI-7104 in August, positive Phase 1 data for oral NLRP3 inhibitor ACI-19764, and positive Part 1 Phase 2 results for ACI-7104 in September. Cash burn and pipeline spend are the items to track against that 2028 runway.
At the time of this announcement, ACIU was trading at $2.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.7M. The 52-week trading range was $2.02 to $3.90. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.